Insulin glargine

DB00047ApprovedInvestigationalProtein Based TherapiesBlood Glucose Lowering AgentsInsulinInsulin Analog

Insulin glargine is a modified form of long-acting or basal insulin used to control hyperglycemia in diabetes mellitus. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism.

Protein structure of Insulin glargine
Mechanism
Curator reviewed
Primary indication
Insulin glargine is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.Curator reviewed · 7 structured indications
Formula / weight
C267H404N72O78S6 · 6063.0 Da
First approval
Canada, 2006 · United States, 2002 · European Union, 2016
Also known as
Insulin glargine (rDNA origin) · Insulin glargine recombinant · insulin glargine-yfgn
Code names
HOE-71GT · HOE-901 · LY-2963016 · MK-1293 · MYL-1501D
Brand names
  • Basaglar
  • Langlara
  • Lantus
  • Rezvoglar
  • Semglee
  • Soliqua
  • Suliqua
  • Suliqua Pen
  • Toujeo

Resolves to

What you can answer from here — as of July 17, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
798Drug interactionsStructured to mechanism, not free text
Sign in
194Clinical trialsPhase, status and sponsor resolved per trial
Sign in
7Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
1ContraindicationEach with its own population and attribute set
Sign in
335Marketed productsAcross 10 countries and 40 labellers
Sign in
2ATC codesIncluding every combination product, plus 21 drug categories
Sign in
27+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Insulin glargine, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account